<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03251131</url>
  </required_header>
  <id_info>
    <org_study_id>HUS/1782/2017</org_study_id>
    <nct_id>NCT03251131</nct_id>
  </id_info>
  <brief_title>REVERSE-AKI Randomized Controlled Pilot Trial</brief_title>
  <acronym>REVERSE-AKI</acronym>
  <official_title>REstricted Fluid Therapy VERsus Standard trEatment in Acute Kidney Injury - REVERSE-AKI Randomized Controlled Pilot Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Helsinki University Central Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Austin Hospital, Melbourne Australia</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Guy's and St Thomas Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University Hospital, Ghent</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Medical University Innsbruck</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Lausanne University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Helsinki University Central Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Observational studies among patients with acute kidney injury (AKI) have shown an association
      with fluid accumulation and increased mortality. Trials among other subgroups of critically
      ill patients have demonstrated that restricting fluid input after the initial resuscitation
      appears safe.

      The objective if this study is to determine whether a fluid restrictive treatment regimen
      will lead to a lower cumulative fluid balance at 72 hours from randomization in critically
      ill patients with AKI and whether this approach is safe and feasible.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Acute kidney injury (AKI) is common in the critically ill and associates with adverse
      outcomes. Patients with AKI are frequently have low urine output and are at high risk of
      developing fluid overload. Fluid overload has been associated with an increased risk for
      mortality in such patients. Previous trials in critically ill patients found that a
      'restrictive fluid therapy' after resuscitation was safe. Implementing a restrictive fluid
      therapy approach in patients with AKI may also be of benefit. To date, however, no randomized
      trial has been performed to evaluate the safety and feasibility of implementing a
      'restrictive fluid therapy' approach compared to standard fluid therapy in patients with AKI.

      In this pilot randomized controlled trial we will evaluate the implementation of a fluid
      restrictive approach, compared to standard therapy, in adult critically ill patients with
      acute kidney injury.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 8, 2017</start_date>
  <completion_date type="Anticipated">March 2019</completion_date>
  <primary_completion_date type="Anticipated">December 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cumulative fluid balance</measure>
    <time_frame>72 hours</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Duration of acute kidney injury</measure>
    <time_frame>ICU discharge/14 days</time_frame>
    <description>Defined according to Kidney Diseases: Improving Global Outcomes criteria</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients requiring renal replacement therapy</measure>
    <time_frame>14 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cumulative fluid balance</measure>
    <time_frame>24 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cumulative fluid balance</measure>
    <time_frame>ICU discharge/ 7 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cumulative dose of diuretics</measure>
    <time_frame>ICU discharge/ 7 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mechanical ventilation free days alive</measure>
    <time_frame>14 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vasopressor free days and alive</measure>
    <time_frame>14 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Renal replacement therapy free days and alive</measure>
    <time_frame>90 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dialysis dependence</measure>
    <time_frame>90 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>All-cause mortality</measure>
    <time_frame>90 days</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Number of serious adverse events and reactions</measure>
    <time_frame>7 days</time_frame>
    <description>Ventricular tachycardia/fibrillation
New onset of atrial fibrillation requiring medication/defibrillation
Ischemic events
i. Acute myocardial infarction ii. Cerebral ischemia verified by CT or MRI scan.
iii. Intestinal ischemia verified by endoscopy or open surgery.
iv. Acute peripheral limb ischemia d. Radiologically diagnosed pulmonary edema e. Adverse events related to renal replacement therapy and diuretics use f. Frequency of hypokalaemia (serum K &lt;3.5mmol/L) g. Frequency of hypomagnesaemia (serum Mg &lt;0.8mmol/L)</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Acute Kidney Injury</condition>
  <condition>Critical Illness</condition>
  <arm_group>
    <arm_group_label>Restrictive fluid management</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Restrictive fluid management Targeting a negative or maximum 300ml positive daily fluid balance.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard therapy</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Randomized allocation of standard care at the clinician's discretion in accordance with current best practice.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Restrictive fluid management</intervention_name>
    <description>Daily fluid input is restricted to drugs and nutrition. Fluid boluses and blood products can be given if clinically indicated. Matching fluid output to fluid input whenever possible using diuretics if needed, and additionally, if clinically necessary and plausible, commencing renal replacement therapy. If renal replacement therapy is not deemed clinically desirable, acceptance of a less than targeted fluid balance.</description>
    <arm_group_label>Restrictive fluid management</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. 18-years or older and admitted to critical care with an arterial line in place

          2. The patient has been in critical care for at least 12 hours but no more than 72 hours

          3. The patient has AKI but is not receiving acute RRT:

             For the purpose of the study AKI is defined the by the following criteria:

               1. Increase in serum creatinine over 1.5-times above baseline without a decline of
                  27umol/l or more from the last preceding measurement (at least 12 hours apart)
                  AND/OR

               2. Overall urine output less than 0.5ml/kg/h (or 6ml/kg) for the previous 12h (with
                  urine catheter in place for the period)

          4. The patient is judged by the treating clinician not to be intravascularly hypovolemic

          5. The patient is likely to remain in critical care for 48 hours after randomization

        Exclusion Criteria:

          1. Active bleeding necessitating transfusion

          2. Maintenance fluid therapy is necessary due to diabetic ketoacidosis, non-ketotic coma,
             severe burns or other clinical reason determined by the medical staff

          3. Need for RRT due to intoxication of a dialyzable toxin

          4. Commencement of RRT is expected in the next 6 hours

          5. On chronic renal replacement therapy (maintenance dialysis or renal transplant)

          6. Presence or a strong clinical suspicion of parenchymal AKI (for example
             glomerulonephritis, vasculitis, acute interstitial nephritis), or post-renal
             obstruction

          7. Severe hyponatremia (Na &lt;125mmol/L) or hypernatremia (Na &gt;155mmol/L)

          8. Need for extracorporeal membrane oxygenation or molecular absorbent recirculating
             system (MARS-therapy)

          9. Pregnant or lactating

         10. Patients who are not to receive full active treatment

         11. No baseline creatinine available

         12. Lack of consent

         13. The patient has been enrolled in another trial where co-enrollment is not feasible
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Suvi Vaara, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Division of Intensive Care Medicine, Department of Anesthesiology, Intensive Care and Pain Medicine, University of Helsinki and Helsinki University Hospital, Helsinki, Finland</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Marlies Ostermann, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Critical Care and Nephrology, King's College London, Guy's and St Thomas Hospital, Foundation Hospital, London</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Suvi Vaara, MD, PhD</last_name>
    <phone>+35894711</phone>
    <email>suvi.vaara@hus.fi</email>
  </overall_contact>
  <location>
    <facility>
      <name>Austin Hospital</name>
      <address>
        <city>Melbourne</city>
        <state>Victoria</state>
        <zip>3048</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Glenn Eastwood, RN, PhD</last_name>
      <email>glenn.eastwood@austin.org.au</email>
    </contact>
    <investigator>
      <last_name>Rinaldo Bellomo</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Innsbruck University Hospital</name>
      <address>
        <city>Innsbruck</city>
        <country>Austria</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Michael Joannidis</last_name>
      <email>michael.joannidis@i-med.ac.at</email>
    </contact>
    <investigator>
      <last_name>Michael Joannidis</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ghent University Hospital</name>
      <address>
        <city>Ghent</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Eric Hoste</last_name>
      <email>eric.hoste@ugent.be</email>
    </contact>
    <investigator>
      <last_name>Eric Hoste</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Helsinki University Hospital</name>
      <address>
        <city>Helsinki</city>
        <country>Finland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Suvi Vaara</last_name>
      <email>suvi.vaara@hus.fi</email>
    </contact>
    <investigator>
      <last_name>Ville Pettilä</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Westfälische Wilhelms-Universität Münster</name>
      <address>
        <city>Münster</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Alexander Zarbock, MD, PhD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Lausanne University Hospital</name>
      <address>
        <city>Lausanne</city>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Antoine Schneider</last_name>
      <email>antoine.schneider@chuv.ch</email>
    </contact>
    <investigator>
      <last_name>Antoine Schneider</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Guy's and St Thomas Hospital</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Marlies Ostermann</last_name>
      <email>marlies.ostermann@gstt.nhs.uk</email>
    </contact>
    <investigator>
      <last_name>Marlies Ostermann</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Austria</country>
    <country>Belgium</country>
    <country>Finland</country>
    <country>Germany</country>
    <country>Switzerland</country>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 12, 2017</study_first_submitted>
  <study_first_submitted_qc>August 12, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">August 16, 2017</study_first_posted>
  <last_update_submitted>May 11, 2018</last_update_submitted>
  <last_update_submitted_qc>May 11, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 14, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Helsinki University Central Hospital</investigator_affiliation>
    <investigator_full_name>Suvi Vaara</investigator_full_name>
    <investigator_title>MD, PhD</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acute Kidney Injury</mesh_term>
    <mesh_term>Critical Illness</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

